Iovance Biotherapeutics Stock Price

0.81 (3.24%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.81 3.24% 25.82 20:00:00
Open Price Low Price High Price Close Price Prev Close
25.32 25.23 27.00 25.82 25.01
Bid Price Ask Price Spread News
25.00 30.78 5.78 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
25,142 2,157,285 $ 26.13 $ 56,359,789 2,233,661 24.50 - 54.2081
Last Trade Time Type Quantity Stock Price Currency
19:26:47 10 $ 27.11 USD

Iovance Biotherapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.95B 152.85M 127.68M $ - $ - -1.89 -14.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 150.00k 13.60%

more financials information »

Iovance Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IOVA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week29.9330.8224.5026.512,700,469-4.11-13.73%
1 Month33.2333.5524.5029.532,153,413-7.41-22.3%
3 Months47.3147.5024.5031.772,199,116-21.49-45.42%
6 Months38.0054.208124.5037.051,695,047-12.18-32.05%
1 Year33.5654.208124.5034.481,636,466-7.74-23.06%
3 Years15.2054.20817.2624.801,502,32710.6269.87%
5 Years4.9954.20814.4522.351,092,22720.83417.43%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Your Recent History
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.